Abstract:Background::Previous studies have provided conflicting evidence about the increased overall survival (OS) in lung cancer patients with diabetes mellitus (DM) compared with those without DM. This study assessed progression-free survival (PFS)/OS in lung cancer patients with or without DM and tentatively analyzed the impact of blood glucose levels on PFS/OS in lung cancer patients.Methods::Data were collected from lung cancer patients based upon admission records from January 2010 to January 2012 and follow-up records from January 2010 to January 2015 in the Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai. The data included patient sex, age, body mass index (BMI), smoking status, history of DM, level of blood glucose, pathological type, clinical stage of cancer, chemotherapy regimen, and history of anti-DM drugs. The Cox regression model and Kaplan-Meier method were used for the analysis of hazard factors and PFS/OS. For comparison of PFS/OS in lung cancer with or without DM, patients were divided into three groups: lung cancer with DM, lung cancer without DM but with elevated level of blood glucose, lung cancer without DM or elevated level of blood glucose.Results::In total, the data from 200 lung cancer patients (138 males/62 females, aged 29.0 to 78.0 years, mean 60.0 ± 8.6 years) were collected. For the comparison of PFS/OS in lung cancer patients with or without DM, patients were divided into three groups: lung cancer with DM ( n = 31); lung cancer without DM but with elevated levels of blood glucose ( n = 40); and lung cancer without both DM and elevated levels of blood glucose ( n = 128), whereas 1 patient dropped out of the study. All the patients underwent complete chemotherapy and were followed up for 36.0 to 60.0 months. Kaplan-Meier survival analysis showed that lung cancer patients with DM had increased PFS and OS compared with those without DM (log-rank, P < 0.05, P < 0.01); the median PFS in lung cancer with DM was 12.0 months (95% confidence interval [CI], 4.0-16.0) vs. 6.0 months in those without DM (95% CI, 5.8-6.3); and the median OS in lung cancer patients with DM was 37.0 months (95% CI, 29.0-46.6) vs. 12.0 months in those without DM (95% CI, 10.9-13.1). For the other two groups of patients without DM, there was a trend toward a shorter PFS and OS in patients with elevated blood glucose compared with those without elevated blood glucose. Cox regression showed that PFS in lung cancer patients was favorably associated with the usage of anti-DM drugs, BMI, clinical stage of cancer, and chemotherapy regimen (all P < 0.05) but was inversely associated with the level of blood glucose ( P < 0.05). Conclusions::Lung cancer patients with DM have prolonged PFS and OS compared with those without DM, and the level of blood glucose was inversely associated with PFS. The current results indicate that PFS may be a meaningful intermediate endpoint for OS and that the levels of blood glucose hopefully represent a prognostic factor in lung cancer patients.

Glycemic control and survival of patients with coexisting diabetes mellitus and gastric or esophageal cancer

Mortality and glycemic control among patients with gastric and esophageal cancer and diabetes mellitus.

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus

P2.15-22 Optimal Glycemic Control Improves Prognosis for Lung Cancer Patients with Diabetes Mellitus

Glycemic control in diabetic patients improved overall lung cancer survival across diverse populations

Prolonged Progression-Free Survival and Overall Survival Are Associated with Diabetes Mellitus but Inversely Associated with Levels of Blood Glucose in Patients with Lung Cancer.

Diabetes Mellitus and Survival of Non‐small Cell Lung Cancer Patients after Surgery: A Comprehensive Systematic Review and Meta‐analysis

Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis.

Optimal glycemic target level for colon cancer patients with diabetes

Effect of diabetes on endometrial cancer recurrence and survival

The Effect of Diabetes on Pathologic Complete Response Among Patients With Esophageal Cancer

Clinical Risk and Overall Survival in Patients with Diabetes Mellitus, Hyperglycemia and Glioblastoma Multiforme. A Review of the Current Literature

Diabetes Mellitus and Poor Glycemic Control Negatively Impact Clinical Outcomes and Survival in Patients with Compensated Cirrhosis

Effects of Diabetes on Inflammatory Status and Prognosis in Cancer Patients.

Study on chemotherapy-induced glycated hemoglobin and fasting plasma glucose disorders of malignant tumor patients

Diabetes Mellitus May Worsen the Prognosis in Hepatocellular Carcinoma Patients Undergoing Curative Microwave Ablation.

Diabetes Mellitus is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma

Impact of Pre-existing Type-2 Diabetes on Patient Outcomes After Radical Resection for Gastric Cancer: A Retrospective Cohort Study

Evaluating the Effect of Diabetes on the Prognosis of Gastric Cancer Using a Propensity Score Matching Method.

Impact of diabetes on the prognosis of patients with oral and oropharyngeal cancer: A meta‐analysis

P-glycoprotein Associated with Diabetes Mellitus and Survival of Patients with Pancreatic Cancer: 8-Year Follow-Up.